Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Neuhaus, O; Archelos, JJ; Hartung, HP.
Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection.
Trends Pharmacol Sci. 2003; 24(3):131-138
Doi: 10.1016%2FS0165-6147%2803%2900028-2
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Co-Autor*innen der Med Uni Graz
- Archelos-Garcia Juan-Jose
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Multiple sclerosis (MS) is the most common disabling neurological disease of young adulthood. Following advances in the understanding of the immunological mechanisms that underlie the pathogenesis of MS, a growing arsenal of immunomodulatory agents is available. Two classes of immunomodulators are approved for long-term treatment of MS, the efficacy of several promising new concepts is being tested in clinical trials and classical immunosuppressive agents used in MS treatment have been shown to exert specific, immunomodulatory effects. Furthermore, two recent observations have changed our basic understanding of the pathogenesis of MS. First, immune cells in MS lesions have neuroprotective activity, which indicates a beneficial role of neuroinflammation. Second, there is evidence that axonal loss, rather than demyelination, underlies the progression of MS and, hence, constitutes a therapeutic target.
- Find related publications in this database (using NLM MeSH Indexing)
- Animals -
- Humans -
- Immunoglobulins, Intravenous - therapeutic use
- Interferons - therapeutic use
- Multiple Sclerosis - drug therapy
- Nerve Growth Factors - therapeutic use
- Neuroprotective Agents - therapeutic use